Researching drugs is an expensive business and from a commercial point of view, it has to be worth the time and expense to develop new medications or otherwise risk any progress in this industry grinding to a halt.
It is one thing, however, for a company to market a drug at a price which enables it to cover its costs, but quite another to inflate prices simply because it can.
It will be interesting to see the outcome of Pfizer's appeal - and find out which one of these categories the company falls into.
Drugs giant Pfizer has been fined a record £84.2m by the UK's competition watchdog for overcharging the NHS for an anti-epilepsy drug. NHS spending on the capsules, used by 48,000 UK patients, rose from £2m a year in 2012 to about £50m in 2013. Pfizer rejected the findings and said it would appeal against the decision. Before 2012, Pfizer manufactured and distributed the drug, which was branded Epanutin. Pfizer then sold the UK rights to distribute the phenytoin sodium capsules to Flynn Pharma, which de-branded the drug. That allowed the firms to charge more for the drug because it was no longer subject to a pricing scheme agreed between the NHS and the drugs industry, the CMA said.